Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao ; 45(5): 743-751, 2023 Oct.
Artículo en Zh | MEDLINE | ID: mdl-37927015

RESUMEN

Objective To investigate the role of ATP citrate lyase(ACLY)in the development of hepatocellular carcinoma(HCC)and the impact of this enzyme on the immune microenvironment of HCC.Methods We utilized the University of Alabama at Birmingham Cancer Data Analysis Portal and the Gene Expression Profiling Interactive Analysis to identify the changes in ACLY expression and prognosis across different tumor types from The Cancer Genome Atlas.With HCC as the disease model,we analyzed the ACLY expression in HCC samples from the gene expression database.Furthermore,we collected the clinical specimens from HCC patients to verify the mRNA and protein levels of ACLY.In addition,we conducted transcriptome sequencing after knocking down the expression of ACLY to analyze the differentially expressed genes and investigated the impact of ACLY expression interference on cell proliferation and other functions.Finally,we explored the correlations of ACLY with immune cells and immune infiltration in the tumor microenvironment,new antigens,and immune checkpoint genes.Results ACLY expression was significantly up-regulated in solid tumors including HCC(all P<0.05),and high ACLY expression was associated with overall survival rate in HCC(P=0.005).Furthermore,high ACLY expression affected the presence of immune cells(e.g.,tumor-associated fibroblasts)and the expression of genes involved in lipid metabolism(all P<0.05).Conclusions ACLY is closely related to the occurrence and development of HCC and lipid metabolism abnormalities.Moreover,it has a specific impact on the immune microenvironment of HCC.


Asunto(s)
ATP Citrato (pro-S)-Liasa , Carcinoma Hepatocelular , Neoplasias Hepáticas , Humanos , ATP Citrato (pro-S)-Liasa/genética , ATP Citrato (pro-S)-Liasa/metabolismo , Relevancia Clínica , Metabolismo de los Lípidos , Microambiente Tumoral
2.
Dig Surg ; 32(6): 433-8, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26402444

RESUMEN

BACKGROUND: CD8+ central memory T cells (CD8+ Tcm) have superior roles in antitumor immunity. The purpose of this study was to detect CD8+ Tcm in the peripheral blood of patients with pancreatic adenocarcinoma and to analyze its clinic significance. METHODS: Seventy two patients with primary pancreatic adenocarcinoma who underwent curative operation were enrolled. The percentage and absolute count of CD8+ Tcm in the peripheral blood of patients were analyzed through flow cytometry and the multiplatform predicate method, respectively, and these values were compared to those of the healthy control. The correlation between CD8+ Tcm and survival was analyzed by the Kaplan-Meier with log-rank test and Cox's regression methods, respectively. RESULTS: The percentage of CD8+ Tcm from pancreatic adenocarcinoma was higher than the healthy control (16.79 ± 9.43% vs. 11.41 ± 4.67%, p = 0.028), which also had a relationship with the lymph node status. Patients with high-level CD8+ Tcm had a significantly higher median survival than those with low CD8+ Tcm (18 vs. 12 months, p = 0.004); a similar result was obtained in absolute CD8+ Tcm count. It was revealed in multivariate analysis that both percentage and absolute count of CD8+ Tcm was an independent prognostic factor for overall survival. CONCLUSIONS: CD8+ Tcm can be considered an independent prognostic factor for operable pancreatic adenocarcinoma, which was also associated with the lymph nodes metastasis.


Asunto(s)
Adenocarcinoma/sangre , Adenocarcinoma/secundario , Linfocitos T CD8-positivos/inmunología , Neoplasias Pancreáticas/sangre , Neoplasias Pancreáticas/patología , Adenocarcinoma/mortalidad , Adenocarcinoma/cirugía , Femenino , Humanos , Inmunidad Celular , Memoria Inmunológica , Metástasis Linfática , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Neoplasias Pancreáticas/mortalidad , Neoplasias Pancreáticas/cirugía , Periodo Preoperatorio , Pronóstico , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA